

# Juan A Vargas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3459063/publications.pdf>

Version: 2024-02-01

53  
papers

1,341  
citations

411340

20  
h-index

406436

35  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2001  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes. <i>Vascular Pharmacology</i> , 2022, 143, 106955.	1.0	3
2	Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 1949.	1.0	4
3	Serum cytokines to predict systemic lupus erythematosus clinical and serological activity. <i>Clinical and Translational Science</i> , 2022, 15, 1676-1686.	1.5	5
4	Hematological- and Immunological-Related Biomarkers to Characterize Patients with COVID-19 from Other Viral Respiratory Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 3578.	1.0	1
5	Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized With COVID-19 in Spain. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e28-e37.	1.7	90
6	The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals. <i>Journal of Clinical Medicine</i> , 2021, 10, 305.	1.0	21
7	El sistema MIR en tiempos del Covid. <i>Revista De Investigaci3n Y Educaci3n En Ciencias De La Salud (RIECS)</i> , 2021, 6, 107-109.	0.0	0
8	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4678.	1.0	3
9	Inflammatory-Related Clinical and Metabolic Outcomes in COVID-19 Patients. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	14
10	Exploring Host Genetic Polymorphisms Involved in SARS-CoV Infection Outcomes: Implications for Personalized Medicine in COVID-19. <i>International Journal of Genomics</i> , 2020, 2020, 1-8.	0.8	19
11	Impacto de la bacteriemia por <i>Pseudomonas aeruginosa</i> en un hospital de tercer nivel: mortalidad y factores pron3sticos. <i>Medicina Cl3nica</i> , 2019, 152, 83-89.	0.3	11
12	Nutrition education in medical schools (NEMS). An ESPEN position paper. <i>Clinical Nutrition</i> , 2019, 38, 969-974.	2.3	41
13	Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model. <i>PLoS ONE</i> , 2016, 11, e0154159.	1.1	5
14	Genotypic distribution of common variants of endosomal toll like receptors in healthy Spanish women. A comparative study with other populations. <i>Gene</i> , 2016, 578, 32-37.	1.0	3
15	Gammapat3as biconales: estudio retrospectivo de 47 pacientes. <i>Revista Clinica Espanola</i> , 2015, 215, 18-24.	0.2	14
16	Authors' reply. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 433-433.	0.6	0
17	Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 54-58.	0.6	32
18	Situaci3n actual de la ense3anza de la Patolog3a General en Espa3a. <i>Revista Clinica Espanola</i> , 2013, 213, 421-427.	0.2	16

#	ARTICLE	IF	CITATIONS
19	CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2010, 38, 165-173.	0.2	3
20	Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 261-270.	0.7	52
21	Prognostic irrelevance of HLA-DR in B-cell chronic lymphocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 327-337.	0.7	21
22	Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 593-603.	0.6	10
23	Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands. <i>International Journal of Immunogenetics</i> , 2008, 35, 235-242.	0.8	26
24	In vitro radiosensitisation by trabectedin in human cancer cell lines. <i>European Journal of Cancer</i> , 2008, 44, 1726-1733.	1.3	22
25	Analysis of Competing Risks of Causes of Death and their Variation Over Different Time Periods in Hodgkin's Disease. <i>Clinical Cancer Research</i> , 2008, 14, 5300-5305.	3.2	11
26	HSP-70 as a nonspecific early marker in cisplatin ototoxicity. <i>Acta Oto-Laryngologica</i> , 2007, 127, 564-567.	0.3	11
27	Association of the microsatellite in the 3' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: a case-control study. <i>Arthritis Research and Therapy</i> , 2007, 9, R89.	1.6	12
28	CD5 does not regulate the signaling triggered through BCR in B cells from a subset of B-CLL patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 147-157.	0.6	4
29	CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. <i>Leukemia Research</i> , 2007, 31, 183-193.	0.4	22
30	Common Variable Immunodeficiency in Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 36, 238-245.	1.6	57
31	Clinical Value of the Ankle-Brachial Index in Patients at Risk of Cardiovascular Disease but Without Known Atherothrombotic Disease: VITAMIN Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2006, 59, 662-670.	0.4	5
32	Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 416-422.	0.7	31
33	Decrease of regulatory T cells in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 553-554.	0.5	97
34	Polymorphism in the CD5 Gene Promoter in B-Cell Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2005, 123, 646-650.	0.4	4
35	A sustained activation of PI3K/NF- $\kappa$ B pathway is critical for the survival of chronic lymphocytic leukemia B cells. <i>Leukemia</i> , 2004, 18, 1391-1400.	3.3	233
36	The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 310-317.	0.5	33

#	ARTICLE	IF	CITATIONS
37	Does the Serological Testing Really Play a Role in the Diagnosis Immune-mediated Inner Ear Disease?. <i>Acta Oto-Laryngologica</i> , 2002, 122, 243-248.	0.3	31
38	Flow-cytometric assessment of lymphocyte cytokine production in tuberculosis. <i>Tuberculosis</i> , 2002, 82, 37-41.	0.8	23
39	Validity of the Western Blot Immunoassay for Heat Shock Protein-70 in Associated and Isolated Immunorelated Inner Ear Disease. <i>Laryngoscope</i> , 2002, 112, 304-309.	1.1	50
40	Giant cell arteritis associated with demyelinating polyradiculoneuropathy. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 812-813.	0.5	6
41	Role of Viral and <i>Mycoplasma pneumoniae</i> infection in Idiopathic Sudden Sensorineural Hearing Loss. <i>Acta Oto-Laryngologica</i> , 2000, 120, 835-839.	0.3	46
42	Aminoguanidine reduces apoptosis of circulating V Beta 8.2 T lymphocytes in Lewis rats with actively induced experimental autoimmune encephalomyelitis. Association with persistent inflammation of the central nervous system and lack of recovery. <i>Journal of Neuroimmunology</i> , 2000, 110, 140-150.	1.1	10
43	More on purine analog-induced apoptosis in B cell chronic lymphocytic leukemia. <i>Leukemia</i> , 1998, 12, 633-633.	3.3	2
44	Reply to Morabito et al. <i>Leukemia</i> , 1998, 12, 634-634.	3.3	2
45	Prognostic Significance of Natural Killer Cell Activity in Patients With Laryngeal Carcinoma. <i>JAMA Otolaryngology</i> , 1998, 124, 852.	1.5	30
46	Acquired pure red cell aplasia: a study of six cases. <i>Annals of Hematology</i> , 1995, 71, 181-183.	0.8	7
47	Natural killer cell activity in patients with pernicious anemia. <i>Digestive Diseases and Sciences</i> , 1995, 40, 1538-1541.	1.1	2
48	Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. <i>International Journal of Cancer</i> , 1995, 60, 235-243.	2.3	26
49	Functional and Phenotypic Analysis of T-lymphocytes in Laryngeal Carcinoma. <i>Acta Oto-Laryngologica</i> , 1994, 114, 663-668.	0.3	5
50	T Lymphocyte Activation in Graves' Disease. <i>Endocrine Research</i> , 1994, 20, 291-306.	0.6	3
51	Natural Killer Cell Activity in Laryngeal Carcinoma. <i>JAMA Otolaryngology</i> , 1993, 119, 69-72.	1.5	14
52	Hepatic fibrin-ring granulomas: A clinicopathologic study of 23 patients. <i>Human Pathology</i> , 1991, 22, 607-613.	1.1	63
53	Pseudotumor cerebri Complicating Typhoid Fever. <i>European Neurology</i> , 1990, 30, 345-346.	0.6	5